肝内胆管细胞癌根治性切除术后临床预后影响因素的研究

doi:10.3877/cma.j.issn.1674-0793.2019.02.004

目的

探讨肝内胆管细胞癌（ICC）行根治性切除（R0切除）术后的独立预后影响因素。

方法

回顾性分析中山大学附属第一医院自2002年1月至2018年8月行R0切除并经病理确诊的237例ICC患者的临床病理及随访资料，采用Kaplan-Meier法构建生存曲线；单因素及多因素COX回归分析筛选影响患者生存预后的独立因素。一致性指数（C-index）、时间依赖性受试者工作特征曲线（ROC曲线）、曲线下面积（AUC）及校准曲线用于评价COX回归模型的预测效能。

结果

237例ICC患者的中位生存期为19.93个月（95%CI=14.31~26.21），术后1、2、3年生存率分别为62.3%、45.0%及35.6%。单因素及多因素回归分析显示谷氨酰转移酶（GGT） >53 U/L（P=0.001）、CA125>17.4 U/ml（P<0.001）、淋巴结转移（P=0.039）、肿瘤分化不良（P<0.001）是ICC患者行R0切除术后预后不良的独立危险因素。按照删除概率P>0.1的标准，纳入癌胚抗原（CEA）（P=0.092）后的预后模型C-index为0.74（95%CI=0.68~0.78），不同随访时间点对应的AUC值均在0.8左右，模型具有良好的预测效能。

结论

GGT、CEA、CA125、淋巴结转移情况及肿瘤分化程度可作为ICC患者R0切除术后临床预后的预测指标。

关键词: 癌，胆管细胞, 肝切除术, 预后, 因素分析，统计学

Objective

To identify the independent prognostic factors of intrahepatic cholangiocarcinoma (ICC) patients after receiving curative (R0) resection.

Methods

From January 2002 to August 2018, the clinicopathological and prognosis data of two hundred and thirty-seven patients with the pathological diagnosis of ICC in the First Affiliated Hospital of Sun Yat-sen University who underwent curative resection were analyzed retrospectively. The survival curve was constructed by Kaplan-Meier method. Univariate and multivariate COX regression analysis were used to screen independent factors affecting survival and prognosis of patients. C-index, ROC curve, AUC curve and calibration curve were used to evaluate the predictive effectiveness of COX regression model.

Results

The median survival time of ICC patients was 19.93 months (95%CI=14.31-26.21), and the 1-, 2-, and 3-year survival rates were 62.3%, 45.0%, and 35.6%, respectively. Univariate and multivariate regression analysis demonstrated that gamma-glutamyl transpeptidase (GGT) >53 U/L (P=0.001), CA125>17.4 U/ml (P<0.001), lymph node metastasis (P=0.039) and poor tumor differentiation (P<0.001) were the adverse factors of prognosis after R0 resection in ICC patients. According to the criteria for deleting probability: P>0.1, the C-index of the prognostic model containing CEA (P=0.092) was 0.74 (95%CI=0.68-0.78). The AUC values corresponding to different follow-up time points were all around 0.8, and the model had good prediction efficiency.

Conclusion

GGT, CEA, CA125, lymph node metastasis and poor tumor differentiation are prognostic predictors of ICC patients after receiving R0 resection.

Key words: Carcinoma, cholangiocellular, Hepatectomy, Prognosis, Factor analysis, statistical

表1 237例行R0切除术的ICC患者临床病理特征分析

项目		例数(%)	项目		例数(%)	项目		例数(%)
年龄(岁)		?	INR		1.0(0.1~2.0)^a	肿瘤大小(cm)		6.0(0.1~16)^a
?	≤60	128(54.0)	?	≤1.07	171(72.2)	?	≤5	81(35.8)
?	>60	109(46.0)	?	>1.07	66(27.8)	?	>5	145(64.2)
性别		?	CA19-9(U/ml)		111.0(0~12 000)^a	肿瘤个数		?
?	男	138(58.2)	?	≤51.4	83(35.0)	?	1	172(75.8)
?	女	99(41.8)	?	>51.4	154(65.0)	?	2~3	19(8.4)
Hb(g/L)		130.0(3.8~178.0)^a	CEA(μg/L)		3.0(0.6~3 203.5)^a	?	>3	36(15.8)
?	≤122	77(32.5)	?	≤3	119(50.2)	血管侵犯		?
?	>122	160(67.5)	?	>3	118(49.8)	?	无	152(64.1)
ALB(g/L)		39.9(20.3~59.0)^a	CA125(U/ml)		20.7(2.6~6 197.6)^a	?	有	85(35.9)
?	≤40	127(53.6)	?	≤17.4	87(36.7)	胆管侵犯		?
?	>40	110(46.4)	?	>17.4	150(63.3)	?	无	197(83.8)
TBIL(μmol/L)		12.0(2.4~412.7)^a	HBsAg		?	?	有	38(16.2)
?	≤18.6	187(78.9)	?	阴性	165(69.6)	局部侵犯		?
?	>18.6	50(21.1)	?	阳性	72(30.4)	?	无	178(75.1)
ALT(U/L)		25.0(5.0~560.0)^a	丙型肝炎		?	?	有	59(24.9)
?	≤49	181(76.4)	?	阴性	227(96.6)	淋巴结转移		?
?	>49	56(23.6)	?	阳性	8(3.4)	?	无	158(66.7)
GGT(U/L)		91.0(12.0~1 776.0)^a	肝硬化		?	?	有	79(33.3)
?	≤53	61(25.7)	?	无	201(84.8)	分化程度		?
?	>53	176(74.3)	?	有	36(15.2)	?	Ⅰ~Ⅱ	115(59.6)
PT(s)		11.9(10.2~131.0)^a	胆管结石		?	?	Ⅲ	78(40.4)
?	≤12.5	180(75.9)	?	无	154(66.7)	术中输血		?
?	>12.5	57(24.1)	?	有	77(33.3)	?	无	157(66.2)
?	?	?	?	?	?	?	有	80(33.8)

表1 237例行R0切除术的ICC患者临床病理特征分析

项目		例数(%)	项目		例数(%)	项目		例数(%)
年龄(岁)		?	INR		1.0(0.1~2.0)^a	肿瘤大小(cm)		6.0(0.1~16)^a
?	≤60	128(54.0)	?	≤1.07	171(72.2)	?	≤5	81(35.8)
?	>60	109(46.0)	?	>1.07	66(27.8)	?	>5	145(64.2)
性别		?	CA19-9(U/ml)		111.0(0~12 000)^a	肿瘤个数		?
?	男	138(58.2)	?	≤51.4	83(35.0)	?	1	172(75.8)
?	女	99(41.8)	?	>51.4	154(65.0)	?	2~3	19(8.4)
Hb(g/L)		130.0(3.8~178.0)^a	CEA(μg/L)		3.0(0.6~3 203.5)^a	?	>3	36(15.8)
?	≤122	77(32.5)	?	≤3	119(50.2)	血管侵犯		?
?	>122	160(67.5)	?	>3	118(49.8)	?	无	152(64.1)
ALB(g/L)		39.9(20.3~59.0)^a	CA125(U/ml)		20.7(2.6~6 197.6)^a	?	有	85(35.9)
?	≤40	127(53.6)	?	≤17.4	87(36.7)	胆管侵犯		?
?	>40	110(46.4)	?	>17.4	150(63.3)	?	无	197(83.8)
TBIL(μmol/L)		12.0(2.4~412.7)^a	HBsAg		?	?	有	38(16.2)
?	≤18.6	187(78.9)	?	阴性	165(69.6)	局部侵犯		?
?	>18.6	50(21.1)	?	阳性	72(30.4)	?	无	178(75.1)
ALT(U/L)		25.0(5.0~560.0)^a	丙型肝炎		?	?	有	59(24.9)
?	≤49	181(76.4)	?	阴性	227(96.6)	淋巴结转移		?
?	>49	56(23.6)	?	阳性	8(3.4)	?	无	158(66.7)
GGT(U/L)		91.0(12.0~1 776.0)^a	肝硬化		?	?	有	79(33.3)
?	≤53	61(25.7)	?	无	201(84.8)	分化程度		?
?	>53	176(74.3)	?	有	36(15.2)	?	Ⅰ~Ⅱ	115(59.6)
PT(s)		11.9(10.2~131.0)^a	胆管结石		?	?	Ⅲ	78(40.4)
?	≤12.5	180(75.9)	?	无	154(66.7)	术中输血		?
?	>12.5	57(24.1)	?	有	77(33.3)	?	无	157(66.2)
?	?	?	?	?	?	?	有	80(33.8)

图1 237例ICC患者R0切除术后生存曲线

表2 237例行R0切除术的ICC患者OS的单因素COX回归分析

项目	HR	95%CI	P值	项目	HR	95%CI	P值
年龄(>60岁)	0.92	0.65~1.31	0.639	丙型肝炎(阳性)	0.73	0.27~1.99	0.542
性别(女)	0.88	0.62~1.26	0.491	合并肝硬化(有)	0.91	0.54~1.52	0.711
Hb(>122 g/L)	0.59	0.41~0.85	0.005^a	胆管结石(有)	1.30	0.90~1.88	0.155
ALB(>40 g/L)	0.65	0.45~0.92	0.017^a	肿瘤大小(>5 cm)	1.68	1.13~2.51	0.011^a
TBIL(>18.6 μmol/L)	1.42	0.94~2.13	0.096	肿瘤数目(个)	?	?	?
ALT(>49 U/L)	1.40	0.96~2.06	0.083	2~3	1.19	0.65~2.19	0.564
GGT(>53 U/L)	2.51	1.56~4.06	<0.001^a	>3	1.82	1.16~2.84	0.009^a
PT(>12.5 s)	1.61	1.10~2.37	0.015^a	血管侵犯(有)	1.89	1.31~2.72	0.001^a
INR(>1.07)	1.45	1.00~2.12	0.051	胆管侵犯(有)	1.01	0.61~1.67	0.967
CA19-9(>51.4 U/ml)	1.89	1.27~2.80	0.002^a	局部侵犯(有)	1.25	0.84~1.86	0.264
CEA(>3 μg/L)	1.68	1.18~2.40	0.004^a	淋巴结转移(有)	1.99	1.39~2.85	<0.001^a
CA125(>17.4 U/ml)	2.65	1.77~3.96	<0.001^a	分化程度(Ⅲ级)	1.67	1.12~2.48	0.012^a
HBsAg(阳性)	1.10	0.76~1.59	0.612	术中输血(有)	1.99	1.40~2.83	<0.001^a

表2 237例行R0切除术的ICC患者OS的单因素COX回归分析

项目	HR	95%CI	P值	项目	HR	95%CI	P值
年龄(>60岁)	0.92	0.65~1.31	0.639	丙型肝炎(阳性)	0.73	0.27~1.99	0.542
性别(女)	0.88	0.62~1.26	0.491	合并肝硬化(有)	0.91	0.54~1.52	0.711
Hb(>122 g/L)	0.59	0.41~0.85	0.005^a	胆管结石(有)	1.30	0.90~1.88	0.155
ALB(>40 g/L)	0.65	0.45~0.92	0.017^a	肿瘤大小(>5 cm)	1.68	1.13~2.51	0.011^a
TBIL(>18.6 μmol/L)	1.42	0.94~2.13	0.096	肿瘤数目(个)	?	?	?
ALT(>49 U/L)	1.40	0.96~2.06	0.083	2~3	1.19	0.65~2.19	0.564
GGT(>53 U/L)	2.51	1.56~4.06	<0.001^a	>3	1.82	1.16~2.84	0.009^a
PT(>12.5 s)	1.61	1.10~2.37	0.015^a	血管侵犯(有)	1.89	1.31~2.72	0.001^a
INR(>1.07)	1.45	1.00~2.12	0.051	胆管侵犯(有)	1.01	0.61~1.67	0.967
CA19-9(>51.4 U/ml)	1.89	1.27~2.80	0.002^a	局部侵犯(有)	1.25	0.84~1.86	0.264
CEA(>3 μg/L)	1.68	1.18~2.40	0.004^a	淋巴结转移(有)	1.99	1.39~2.85	<0.001^a
CA125(>17.4 U/ml)	2.65	1.77~3.96	<0.001^a	分化程度(Ⅲ级)	1.67	1.12~2.48	0.012^a
HBsAg(阳性)	1.10	0.76~1.59	0.612	术中输血(有)	1.99	1.40~2.83	<0.001^a

表3 ICC患者R0切除术后OS的多因素COX回归模型

变量	Coef.	Std.Err	HR	95%CI	P值
GGT(>53 U/L)	0.98	2.89	2.68	1.52~4.71	0.001
CEA(>3 μg/L)	0.36	0.22	1.44	0.94~2.20	0.092
CA125(>17.4 U/ml)	0.96	0.24	2.61	1.63~4.17	<0.001
淋巴结转移	0.44	0.21	1.55	1.02~2.36	0.039
分化程度(Ⅲ级)	0.84	0.21	2.31	1.52~3.50	<0.001

表3 ICC患者R0切除术后OS的多因素COX回归模型

变量	Coef.	Std.Err	HR	95%CI	P值
GGT(>53 U/L)	0.98	2.89	2.68	1.52~4.71	0.001
CEA(>3 μg/L)	0.36	0.22	1.44	0.94~2.20	0.092
CA125(>17.4 U/ml)	0.96	0.24	2.61	1.63~4.17	<0.001
淋巴结转移	0.44	0.21	1.55	1.02~2.36	0.039
分化程度(Ⅲ级)	0.84	0.21	2.31	1.52~3.50	<0.001

图2 237例ICC患者根治术后生存的COX回归模型时间依赖性AUC曲线拟合图　实线是拟合线，两边的虚线是95%CI

图3 237例ICC患者根治术后生存的COX回归模型校准曲线

[1]	Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification[J]. J Hepatobiliary Pancreat Surg, 2003, 10(4): 288-291.
[2]	Bridgewater J,Galle PR,Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2014, 60(6): 1268-1289.
[3]	Endo I,Gonen M,Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection[J]. Ann Surg, 2008, 248(1): 84-96.
[4]	Rizvi S,Khan SA,Hallemeier CL, et al. Cholangiocarcinoma-evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018, 15(2): 95-111.
[5]	Wang Y,Li J,Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy[J]. J Clin Onco, 2013, 31(9): 1188-1195.
[6]	Edge SB,Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010, 17(6): 1471-1474.
[7]	Chun YS,Pawlik TM,Vauthey JN. 8th edition of the AJCC Cancer Staging Manual: pancreas and hepatobiliary cancers[J]. Ann Surg Oncol, 2018, 25(4): 845-847.
[8]	Okabayashi T,Yamamoto J,Kosuge T, et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables[J]. Cancer, 2001, 92(9): 2374-2383.
[9]	Nathan H,Aloia TA,Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2009, 16(1): 14-22.
[10]	de Jong MC,Nathan H,Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment[J]. J Clin Oncol, 2011, 29(23): 3140-3145.
[11]	Weber SM,Ribero D,O'Reilly EM, et al. Intrahepatic cholangiocarcinoma: expert consensus statement[J]. HPB (Oxford), 2015, 17(8): 669-680.
[12]	Kim DH,Choi DW,Choi SH, et al. Is there a role for systematic hepatic pedicle lymphadenectomy in intrahepatic cholangiocarcinoma? A review of 17 years of experience in a tertiary institution[J]. Surgery, 2015, 157(4): 666-675.
[13]	Choi SB,Kim KS,Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival[J]. Ann Surg Oncol, 2009, 16(11): 3048-3056.
[14]	Chen T,Zhang MG,Xu HX, et al. Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma[J]. Medicine (Baltimore), 2015, 94(19): e751.
[15]	Higashi M,Yamada N,Yokoyama S, et al. Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type[J]. Pathobiology, 2012, 79(2): 101-106.
[16]	Hu HJ,Mao H,Tan YQ, et al. Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma[J]. Springerplus, 2016, 5: 551.
[17]	Li T,Qin LX,Zhou J, et al. Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection[J]. Liver Int, 2014, 34(6): 953-960.
[18]	Zhang C,Wang H,Ning Z, et al. Serum liver enzymes serveas prognostic factors in patients with intrahepatic cholangio-carcinoma[J]. Onco Targets Ther, 2017, 10: 1441-1449.
[19]	Ou Y,Huang J,Yang L. The prognostic significance of pretreatment serum γ-glutamyltranspeptidase in primary liver cancer: a meta-analysis and systematic review[J]. Biosci Rep, 2018, 38(6): pii: BSR20181058. Print 2018 Dec 21.
[20]	Luo C,Xu B,Fan Y, et al. Preoperative gamma-glutamyltransferase is associated with cancer-specific survival and recurrence-free survival of nonmetastatic renal cell carcinoma with venous tumor thrombus[J]. Biomed Res Int, 2017, 2017: 3142926.
[21]	Everhart JE,Wright EC. Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV)[J]. Hepatology, 2013, 57(5): 1725-1733.
[22]	Pandur S,Pankiv S,Johannessen M, et al. Gamma-glutamyltransferase is upregulated after oxidative stress through the Ras signal transduction pathway in rat colon carcinoma cells[J]. Free Radic Res, 2007, 41(12): 1376-1384.
[23]	Das V,Kalita J,Pal M. Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges[J]. Biomed Pharmacother, 2017, 87: 8-19.
[24]	He C,Zhang Y,Song Y, et al. Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma[J]. J Cancer, 2018, 9(17): 3117-3128.
[25]	Loosen SH,Roderburg C,Kauertz KL, et al. CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma[J]. Sci Rep, 2017, 7(1): 16975.
[26]	Okubo S,Mitsunaga S,Kato Y, et al. The prognostic impact of differentiation at the invasive front of biliary tract cancer[J]. J Surg Oncol, 2018, 117(6): 1278-1287.
[27]	Addeo P,Jedidi I,Locicero A, et al. Prognostic impact of tumor multinodularity in intrahepatic cholangiocarcinoma[J]. J Gastrointest Surg, 2018 Nov 26. [Epub ahead of print]

[1]	许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2]	李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[3]	高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4]	李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5]	冯旺, 马振中, 汤林花. CT扫描三维重建在肝内胆管细胞癌腹腔镜肝切除术中的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 104-107.
[6]	赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[7]	唐梅, 周丽, 牛岑月, 周小童, 王倩. ICG荧光导航的腹腔镜肝切除术临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 655-658.
[8]	屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[9]	杭轶, 杨小勇, 李文美, 薛磊. 可控性低中心静脉压技术在肝切除术中应用的最适中心静脉压[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 813-817.
[10]	刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[11]	陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[12]	曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[13]	沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[14]	王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15]	郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Prognostic factors of intrahepatic cholangiocarcinoma patients undergoing curative resection

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Prognostic factors of intrahepatic cholangiocarcinoma patients undergoing curative resection